We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Patterson Companies, Inc. (PDCO - Free Report) has had an unimpressive run on the bourses in the last three months, trading below the industry. Further, lackluster performance in the dental segment along with a downbeat guidance is a concern. The stock has a Zacks Rank #5 (Strong Sell).
The estimate revision trend for Patterson Companies has been dismal. For the current year, eight analysts moved south compared with no movement in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for full-year earnings fell 9.2% to $2.09.
What’s Not Right in the Dental Segment?
Loss of Distribution Rights
The recent loss of exclusive distribution rights with Dentsply Sirona (XRAY - Free Report) has forced the company to shift to a new enterprise resource planning (ERP) system to efficiently manage inventory. However, the system is creating short-term challenges. Undoubtedly, the termination of the contract presents new opportunities for Patterson Companies to expand distribution platform to a wider range of product offerings. However, the company also witnesses a heavy initial impact from the loss of this deal.
Deteriorating Sales
Patterson Companies’ decision to end exclusive distribution will affect results through fiscal 2018. In fact, the dental segment sales have been sluggish over the last couple of quarters. Management has provided a dull guidance for the coming quarters as well.
In the last quarter, dental sales (40% of total sales) declined 8.4% at cc year over year to approximately $553.6 million. The downside was caused by lower sales of CEREC and digital technology products. Management expects headwinds in the technology-based equipment business to persist through fiscal 2018, adding to the company’s woes.
Competition Rife
Cutthroat competition in the U.S. dental products distribution industry is a major dampener as well. Notably, Patterson Companies faces serious competition from at least 15 full-service distributors that include Henry Schein Dental, a unit of Henry Schein (HSIC - Free Report) , and numerous small and local distributors.
Shares Lack Luster
A rapidly changing healthcare environment in the United States, unfavorable price movements, a competitive dental products distribution industry and integration risks pose significant challenges. Patterson Companies’ price movement in the past three months has been disappointing. The company represented a negative return of almost 5.2%, comparing unfavorably with the industry’s rally of almost 4.7%. In fact, the current level is lower than the S&P 500 index’s return of 7.3% over the same time period.
Key Pick
A top-ranked stock in the broader medical sector is PetMed Express, Inc. (PETS - Free Report) . PetMed has a long-term expected earnings growth rate of 10%. This Zacks Rank #1 (Strong Buy) stock has rallied roughly 76.8% in a year. You can see the complete list of today’s Zacks #1 Rank stocks here.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Patterson Companies' (PDCO) Dental Segment Shows Weakness
Patterson Companies, Inc. (PDCO - Free Report) has had an unimpressive run on the bourses in the last three months, trading below the industry. Further, lackluster performance in the dental segment along with a downbeat guidance is a concern. The stock has a Zacks Rank #5 (Strong Sell).
The estimate revision trend for Patterson Companies has been dismal. For the current year, eight analysts moved south compared with no movement in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for full-year earnings fell 9.2% to $2.09.
What’s Not Right in the Dental Segment?
Loss of Distribution Rights
The recent loss of exclusive distribution rights with Dentsply Sirona (XRAY - Free Report) has forced the company to shift to a new enterprise resource planning (ERP) system to efficiently manage inventory. However, the system is creating short-term challenges. Undoubtedly, the termination of the contract presents new opportunities for Patterson Companies to expand distribution platform to a wider range of product offerings. However, the company also witnesses a heavy initial impact from the loss of this deal.
Deteriorating Sales
Patterson Companies’ decision to end exclusive distribution will affect results through fiscal 2018. In fact, the dental segment sales have been sluggish over the last couple of quarters. Management has provided a dull guidance for the coming quarters as well.
In the last quarter, dental sales (40% of total sales) declined 8.4% at cc year over year to approximately $553.6 million. The downside was caused by lower sales of CEREC and digital technology products. Management expects headwinds in the technology-based equipment business to persist through fiscal 2018, adding to the company’s woes.
Competition Rife
Cutthroat competition in the U.S. dental products distribution industry is a major dampener as well. Notably, Patterson Companies faces serious competition from at least 15 full-service distributors that include Henry Schein Dental, a unit of Henry Schein (HSIC - Free Report) , and numerous small and local distributors.
Shares Lack Luster
A rapidly changing healthcare environment in the United States, unfavorable price movements, a competitive dental products distribution industry and integration risks pose significant challenges. Patterson Companies’ price movement in the past three months has been disappointing. The company represented a negative return of almost 5.2%, comparing unfavorably with the industry’s rally of almost 4.7%. In fact, the current level is lower than the S&P 500 index’s return of 7.3% over the same time period.
Key Pick
A top-ranked stock in the broader medical sector is PetMed Express, Inc. (PETS - Free Report) . PetMed has a long-term expected earnings growth rate of 10%. This Zacks Rank #1 (Strong Buy) stock has rallied roughly 76.8% in a year. You can see the complete list of today’s Zacks #1 Rank stocks here.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>